Schayowitz Adam
Known title: EVP, Head of R&DCIK: 0002127119
Associated companies
Transaction History
| ZYME | ▲ Buy | Option Exercise | 37,037 | $0 | 10/9/2026 | View on chart |
| ZYME | ▼ Sell | Open Market | 13,832 | $358K | 10/9/2026 | View on chart |
| ZYME | ▲ Buy | Option Exercise | 37,037 | $0 | 10/9/2026 | View on chart |
| ZYME | ▼ Sell | Open Market | 13,832 | $358K | 10/9/2026 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
ZYME News Highlights Potential Undervaluation and Raised Price Target
Recent coverage notes that Zymeworks may be about 39% undervalued based on its 2026 revenue guidance and the recent appointment of a chief investment officer. Truist Securities also kept its rating and lifted its price target to $34, reflecting continued confidence in the company's outlook.
ZYME News Highlights Potential Undervaluation and Raised Price Target. Recent coverage notes that Zymeworks may be about 39% undervalued based on its 2026 revenue guidance and the recent appointment of a chief investment officer. Truist Securities also kept its rating and lifted its price target to $34, reflecting continued confidence in the company's outlook.